Picumeterol (GR114297A) is a potent and highly selective beta2-adrenoceptor agonist with a longer duration of action than salbutamol, but shorter than salmeterol. Picumeterol is the (R)-isomer of the racemic entity GR63411B, and picumeterol has been shown to be about 40 times more potent than the (S)-isomer (GR114744A) in various in vitro pharmacological models of beta2-agonist activity. Picumeterol is of potential value in the treatment of asthma and related diseases in man following inhalation administration. In the clinical studies, the bronchodilator potencies of picumeterol and GR 63411B were similar. However, both drugs were short-acting, which is at odds with their activity in vitro. These compounds display dissociation between bronchodilator activity and protection against methacholine-induced bronchoconstriction.

Ceftioxide is broad-spectrum , beta-lactam antibiotic patented by German pharmaceutical company Hoechst A.-G.

Cefuroxime Pivoxetil is an ester prodrug of cefuroxime, a semisynthetic, broad-spectrum, beta-lactamase-resistant, second-generation cephalosporin with antibacterial activity. Cefuroxime binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Primidolol (also known as UK-11,443) is an imidazolidinone derivative patented by American pharmaceutical corporation Pfizer Corp as a specific β-adrenergic blocker. In clinical trials, Primidolol shows some antihypertensive activity but the overall change in the cardiovascular parameters failed to demonstrate a significant difference compared to placebo.

Cimaterol is a chemically stable nonselective agonist β1-, β2-, and β3-adrenoceptors. Cimaterol is used in sport as a stimulant and a fat burner that assists bodybuilders and strength athletes to get rid of body fats. Aside from shedding off fats, another benefit for using cimaterol for athletes is a boost in strength as well as an increase in muscle size or lean body mass. The increase in muscle size has been seen in previous animal studies when cimaterol is used. However, the reason behind the muscle gain is not identified yet, but the body has a very different response compared from taking in anabolic steroids. Experts in the field are saying that the increased nitrogen retention, that is known to cause by cimaterol, maybe the reason behind the muscle gain. Another great thing about Cimaterol is that, it can improve blood flow.

Colterol is a beta-2 adrenoreceptor agonist. Bitolterol, a diester prodrug of colterol, was marketed by Elan Pharmaceuticals for the treatment of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases.

Fuzlocillin is a penicillin antibiotic. This semisynthetic acylureidopenicillin with antibacterial activity binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Fuzlocillin (furazlocillin), has been shown to be highly specific for the FtsI gene. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing the cell to break down (cell lysis). Among the acylureidopenicillins, furaclocillin exerts increased activity against Escherischia coli, Klebsiella, Proteus and Pseudomonas aeruginosa.

Cefoxazole is a semi-synthetic, first-generation cephalosporin with bactericidal activity against penicillin-resistant strains of S. aureus and used in the treatment of bovine mastitis.

Cefivitril is a semi-synthetic cephalosporin with broad antibacterial activity against penicillin-resistant strains of S. aureus. Compared with the other cephalosporin, Cefivitril showed a better in vitro activity on gram pos. and gram neg. bacteria. Sensitivity tests were performed with 1007 bacterial strains to evaluate the in vitro activity of Cefivitril compared with that of cefuroxime and cephapirin. Compared with cefuroxiime and cephaprin, Cefivitril activity was significantly higher on Pasteurella and Salmonella, whereas no significant differences were detected for Streptococcus, Proteus, and Pseudomonas.